Payne J P, Hughes R
Br J Anaesth. 1981 Jan;53(1):45-54. doi: 10.1093/bja/53.1.45.
Atracurium is a potent competitive neuromuscular blocking agent in anesthetized man with no cardiovascular effects at doses required for paralysis. Endotracheal intubation can be accomplished after i.v. doses of 0.6 and 0.3 mg kg-1, within 1 and 2 min respectively. Paralysis is readily antagonized by neostigmine and is enhanced by halothane. The consistent response in terms of block and recovery which emerged when the drug was given as increments of 0.05 or 0.1 mg kg-1 indicates the absence of cumulative effects. The course of action of atracurium was appreciably shorter than that of other recognized competitive blocking agents. Doses of 0.3--0.6 mg kg-1 i.v. provided adequate relaxation during surgical intervention for 15--45 min; spontaneous recovery without the use of neostigmine was observed in some patients. In addition to the non-enzymic decomposition by "Hofmann Elimination", atracurium may also undergo an enzymic ester hydrolysis but, unlike suxamethonium, it may not be destroyed by pseudocholinesterase.
阿曲库铵是一种强效竞争性神经肌肉阻滞剂,在麻醉的人体中,产生麻痹所需剂量下对心血管无影响。静脉注射剂量为0.6和0.3mg/kg时,分别在1分钟和2分钟内可完成气管插管。新斯的明能轻易拮抗麻痹作用,氟烷可增强此作用。当以0.05或0.1mg/kg的增量给药时,在阻滞和恢复方面出现的一致反应表明不存在累积效应。阿曲库铵的作用过程明显短于其他公认的竞争性阻滞剂。静脉注射0.3 - 0.6mg/kg的剂量在手术干预期间可提供15 - 45分钟的充分松弛;一些患者在未使用新斯的明的情况下观察到自发恢复。除了通过“霍夫曼消除”进行非酶分解外,阿曲库铵还可能进行酶促酯水解,但与琥珀胆碱不同,它可能不会被假性胆碱酯酶破坏。